←Back to Expert Scholars
Translational Medicine / 转化医学AML Stem Cells, CD47
Ravindra Majeti
MD, PhD
🏢Stanford University🌐USA
Professor of Medicine
85
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Ravi Majeti identified CD47 as a "don't eat me" signal on leukemic stem cells and translated this discovery into magrolimab clinical trials. He also characterized preleukemic HSCs that persist through chemotherapy and seed relapse in AML.
Share:
🧪Research Fields 研究领域
AML stem cells
CD47 targeting
preleukemic HSC
magrolimab
leukemic evolution
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Ravindra Majeti 的研究动态
Follow Ravindra Majeti's research updates
留下邮箱，当我们发布与 Ravindra Majeti（Stanford University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment